HOME >> BIOLOGY >> NEWS
Novel AIDS-Directed Technology: Approach Permits Optimization Of Existing Drug Therapies And Targeted, Patient-Specific Treatment

State College, PA-- February 3, 1998 -- SpectruMedix Corporation (OTC:SMDX) jointly with The University of California at Berkeley and the University of California at San Francisco announced today in Chicago at the 5th Conference on Retroviruses and Opportunistic Infections, initial in vivo results of T cell proliferation rates in AIDS patients using isotope mass spectrometric techniques. The results are part of an ongoing collaboration designed to change the diagnosis and management of AIDS and to optimize its therapeutic approach by allowing physicians to rapidly measure the efficacy of a drug or treatment modality in an individual patient. This diagnostic technique may finally allow physicians to establish, based upon objective evidence, the proper time for an individual AIDS patient to begin taking medication and which medication is best suited for this particular individual. (A description of this new technique was published in the January 20, 1998 issue of The Proceedings of The National Academy of Sciences: "Measurement of Cell Proliferation etc.". )

The results of this study indicate that the body's capacity to make new cells was in fact the key determinant of T cell counts and the patients' responses to protease inhibitor therapy in AIDS. T cells were indeed being destroyed with a higher degree of efficiency in AIDS patients than in healthy people without HIV infection, but more important is their body's capacity to form new cells.

"We at Berkeley/UCSF are very excited about the prospects for this technology ," stated Marc Hellerstein, M.D., Ph.D., the Principal Investigator of the study. "We are delighted to be working with SpectruMedix with the goal of commercializing this technique at the earliest time. We anticipate that potential beneficiaries will include AIDS, cancer, osteoporosis, heart patients and others."

"The implications of the technology's capability to quickly and accurately monito
'"/>

Contact: Bernard Sonnenschein
bernard@spectrumedix.com
814-867-8600
SpectruMedix Corporation
3-Feb-1998


Page: 1 2 3 4

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: